As previously reported by BioSpace, a group of scientists from the Babraham Institute in the United Kingdom was able to successfully rejuvenate skin cells by a full 30 years.
EVERSANA, a pioneer of next generation commercial services to the global life sciences industry, opened a new office in the heart of London’s Holborn district to serve the company’s growing client and team needs.
Scientists from the United Kingdom may have identified several more environmental causes for cancer after evaluating the genetic data of over 12,000 cancer patients from National Health Service files.
British employees of pharma giant GlaxoSmithKline voted to strike against the company’s recent pay raise. Hundreds of GSK workers backed by British labor union Unite demanded a higher raise, citing major inflation rates and the company’s recent financial successes.
Worldwide demand for Pfizer Inc.’s oral COVID-19 antiviral treatment Paxlovid has been unexpectedly light due to complicated eligibility requirements, reduced testing and potential for drug interactions, a Reuters review of data and interviews with experts found.
A sub-variant of the highly transmissible Omicron version of coronavirus known as BA.2 is now dominant worldwide, prompting surges in many countries in Europe and Asia and raising concern over the potential for a new wave in the United States.
Many countries around the world that appeared to have kicked COVID-19 are reporting surges, largely the result of the so-called “stealth” Omicron variant, BA.2.
A large study into rare blood clots linked with AstraZeneca’s COVID-19 vaccine found between just one and three cases per million, and only after the first dose, shedding fresh light on the side effects from the shot.
Malaysian researchers found that treatment with the anti-parasite drug ivermectin did not prevent patients with COVID-19 from becoming severely ill in a randomized clinical trial published in the JAMA Internal Medicine journal on February 18.
Novavax Inc. delivered just a small fraction of the 2 billion COVID-19 shots the company plans to send around the world in 2022 and has delayed first-quarter shipments in Europe and lower income countries such as the Philippines, public officials involved in their government’s vaccine rollouts told Reuters.